Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Robinson, Giles W ^a   Orr, Brent A ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

BRAF inhibitors; BRAF mutations; Glioblastoma multiforme; High grade glioma; Pediatric brain tumor; V600E

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; GLUTAMIC ACID; TOPOTECAN; VALINE; VEMURAFENIB; VORINOSTAT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADD ON THERAPY; ALOPECIA; ARTICLE; BRAF V600E GENE; BRAIN SURGERY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CAUCASIAN; CHILD; CRANIOTOMY; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; EYE DISEASE; FRONTAL LOBE; GENE MUTATION; GLIOBLASTOMA; HAIR DISEASE; HUMAN; HUMAN TISSUE; MALE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; MUTANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIMARY TUMOR; RECOMMENDED DRUG DOSE; SCHOOL CHILD; STEREOTAXIC SURGERY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; GENETICS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PEDIATRICS;

CHILD; GLIOBLASTOMA; HUMANS; INDOLES; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PEDIATRICS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84899485468     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-258     Document Type: Article

References (20)

1. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121:397-405. 10.1007/s00401-011-0802-6, 21274720.
2. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013, 37:685-698. 10.1097/PAS.0b013e31827f9c5e, 23552385.
3. Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 2012, 5:430-436.
4. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010, 70:512-519. 10.1158/0008-5472.CAN-09-1851, 2851233, 20068183.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendor F. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114. 10.1056/NEJMoa1203421, 22663011.
6. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901. 10.1016/S0140-6736(12)60398-5, 22608338.
7. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103. 10.1038/nature10868, 22281684.
8. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clinical Oncol Off J Am Soc Clinical Oncol 2007, 25:2306-2312.
9. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol 2013, 114:237-240. 10.1007/s11060-013-1176-5, 23756728.
10. Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:e159-e160.
11. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2013, doi:10.1002/pbc.24891.
12. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy S, Gupta G, Pisapia DJ, Canoll P, Bruce JN, Mclendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Prive GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141-1149. 10.1038/ng.2734, 3799953, 23917401.
13. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013, 110:5957-5962. 10.1073/pnas.1219232110, 3625308, 23533272.
14. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714. 10.1056/NEJMoa1112302, 3724515, 22356324.
15. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012, 367:2316-2321. 10.1056/NEJMoa1208958, 3627494, 23134356.
16. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215. 10.1056/NEJMoa1105358, 3724537, 22256804.
17. Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:51-e448.
18. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo R. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 3143360, 21107323.
19. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Petel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703. 10.1056/NEJMoa1210093, 3549295, 23020132.
20. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 2013, 14:e60-e69. 10.1016/S1470-2045(12)70539-9, 23369684.